Biweekly paclitaxel as second-line treatment in advanced non-small-cell-lung-cancer (NSCLC).: A phase II study of the Galician Lung Cancer Group

被引：0
|
作者：
Vazquez-Estevez, S. [1 ]
Firvida, J. L. [2 ]
Grande, C. [3 ]
Baron, F. [4 ]
Lazaro, M. [5 ]
Salgado, M. [2 ]
Campos, B. [1 ]
Casal, J. [3 ]
Perez, E. [2 ]
Mel, J. R. [1 ]
机构：
[1] Complexo Hosp Xeral Calde, Lugo, Spain
[2] Complexo Hosp Ourense, Orense, Spain
[3] Hosp Meixoeiro, Vigo, Spain
[4] Complexo Hosp Univ Santiago, Santiago De Compostela, Spain
[5] Complexo Hosp Xeral Cies, Vigo, Spain
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)71443-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6615
引用
收藏
页码：392 / 392
页数：1
相关论文
共 50 条
  • [1] Biweekly paclitaxel as second-line treatment in advanced non-small cell lung-cancer (NSCLC). A phase II study of the Lung Cancer Galician Group
    Vazquez-Estevez, S.
    Firvida, J.
    Huidobro, G.
    Leon, L.
    Lazaro, M.
    Salgado, M.
    Mel, J.
    Grande, C.
    Perez, E.
    Campos, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Biweekly docetaxel and vinorelbine as second-line treatment in advanced (stage IIIB+ IV) non-small-cell lung cancer (NSCLC).: A phase II study of the Galician Lung Cancer Group
    Vázquez, S
    Villanueva, M
    Amenedo, M
    Fírvida, J
    Lázaro, M
    Del Rio, L
    Huidobro, G
    Mei, J
    Ramos, M
    Grande, C
    LUNG CANCER, 2005, 49 : S273 - S273
  • [3] Biweekly docetaxel and vinorelbine as second-line treatment in advanced (stage IIIB plus IV) non-small-cell lung cancer (NSCLC).: A phase II study of the galician lung cancer group.
    Vázquez, S
    Huidobro, G
    Amenedo, M
    Firvida, JL
    Lázaro, M
    Del Río, L
    Villanueva, MJ
    Alvarez, E
    Ramos, M
    Casal, J
    Xeral, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 703S - 703S
  • [4] Biweekly docetaxel as second-line chemotherapy of patients with advanced non-small cell lung cancer:: a phase II study of the Galician Lung Cancer Group (GGCP 006-00)
    Vázquez, S
    Grande, C
    Amenedo, M
    Fírvida, JL
    Lázaro, M
    Alonso, G
    Curiel, T
    Huidobro, G
    Mel, JR
    Ramos, M
    ANTI-CANCER DRUGS, 2004, 15 (05) : 489 - 494
  • [5] Second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC)
    Ardizzoni, A
    Tiseo, M
    JOURNAL OF CHEMOTHERAPY, 2004, 16 : 104 - 107
  • [6] Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer
    Ceresoli, GL
    Gregorc, V
    Cordio, S
    Bencardino, KB
    Schipani, S
    Cozzarini, C
    Bordonaro, R
    Villa, E
    LUNG CANCER, 2004, 44 (02) : 231 - 239
  • [7] Biweekly docetaxel as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) 2: A phase II study of the Galician Lung Cancer Group
    Vazquez-Estevez, S.
    Leon, L.
    Firvida, J. L.
    Grande, C.
    Vazquez, F.
    Salgado, M.
    Casal, J.
    Baron, F. J.
    Abal, J.
    Garcia, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] Low-dose weekly paclitaxel as second-line treatment for advanced non-small cell lung cancer:: a phase II study
    Juan, O
    Albert, A
    Ordoño, F
    Casany, R
    Carañana, V
    Campos, JM
    Alberola, V
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2002, 32 (11) : 449 - 454
  • [9] A PHASE II STUDY OF DOCETAXEL MONOTHERAPY IN SECOND-LINE TREATMENT IN PRETREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
    Reza, M. S.
    Hai, M. A.
    Chowdhury, Q.
    ANNALS OF ONCOLOGY, 2008, 19 : 119 - 120
  • [10] Weekly docetaxel as a second-line treatment for advanced non-small cell lung cancer (NSCLC).
    García, R
    Pérez, P
    Alfonso, R
    Pérez-Manga, G
    Díaz-Rubio, E
    ANNALS OF ONCOLOGY, 2000, 11 : 116 - 116
12345